Wells Fargo & Company Raises Savara (NASDAQ:SVRA) Price Target to $9.00

Savara (NASDAQ:SVRA) had its price target lifted by investment analysts at Wells Fargo & Company from $7.00 to $9.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target suggests a potential upside of 48.39% from the stock’s current price.

SVRA has been the subject of a number of other reports. Citigroup restated an “outperform” rating on shares of Savara in a report on Thursday, October 23rd. Wall Street Zen raised Savara from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Citizens Jmp decreased their price objective on shares of Savara from $11.00 to $10.00 and set a “market outperform” rating for the company in a report on Thursday, November 13th. Lifesci Capital upgraded Savara to a “strong-buy” rating in a report on Tuesday, October 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Savara currently has an average rating of “Moderate Buy” and a consensus price target of $8.57.

Savara Trading Down 0.7%

SVRA traded down $0.05 during mid-day trading on Thursday, reaching $6.07. The stock had a trading volume of 314,500 shares, compared to its average volume of 1,553,978. Savara has a 52 week low of $1.89 and a 52 week high of $7.01. The firm’s fifty day simple moving average is $4.83 and its two-hundred day simple moving average is $3.53. The company has a debt-to-equity ratio of 0.32, a quick ratio of 7.65 and a current ratio of 7.65. The stock has a market capitalization of $1.23 billion, a P/E ratio of -11.39 and a beta of 0.23.

Savara (NASDAQ:SVRA) last posted its earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01). On average, equities analysts predict that Savara will post -0.45 EPS for the current year.

Institutional Trading of Savara

Institutional investors and hedge funds have recently made changes to their positions in the stock. VR Adviser LLC increased its stake in shares of Savara by 172.7% in the second quarter. VR Adviser LLC now owns 8,884,263 shares of the company’s stock worth $20,256,000 after buying an additional 5,626,624 shares during the last quarter. Bain Capital Life Sciences Investors LLC boosted its holdings in Savara by 20.8% during the first quarter. Bain Capital Life Sciences Investors LLC now owns 17,600,621 shares of the company’s stock worth $48,754,000 after buying an additional 3,035,164 shares in the last quarter. Frazier Life Sciences Management L.P. lifted its position in shares of Savara by 32.4% in the 1st quarter. Frazier Life Sciences Management L.P. now owns 11,462,301 shares of the company’s stock valued at $31,751,000 after acquiring an additional 2,801,922 shares in the last quarter. Rosalind Advisors Inc. increased its holdings in shares of Savara by 50.7% in the 3rd quarter. Rosalind Advisors Inc. now owns 4,000,000 shares of the company’s stock valued at $14,280,000 after purchasing an additional 1,345,056 shares during the period. Finally, Millennium Management LLC acquired a new stake in shares of Savara during the 3rd quarter valued at about $3,014,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.